Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016
Published Jun 30, 2016
68 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016, provides in depth analysis on Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) targeted pipeline therapeutics.

The report provides comprehensive information on the Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL)
- The report reviews Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) targeted therapeutics and enlists all their major and minor projects
- The report assesses Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) targeted therapeutics

Reasons to buy

- Gain strategically significant competit

  
Source:
Document ID
GMDHC0183TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Overview71
Therapeutics Development83
  Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Products under Development by Stage of Development81
  Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Products under Development by Therapy Area91
  Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Products under Development by Indication101
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Products under Development by Companies132
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Products under Development by Universities/Institutes152
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Therapeutics Assessment176
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action181
  Assessment by Route of Administration192
  Assessment by Molecule Type212
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Companies Involved in Therapeutics Development237
  3SBio Inc.231
  Amgen Inc.241
  Eisai Co., Ltd.251
  Intas Pharmaceuticals Ltd.261
  Novartis AG271
  Shionogi &Co., Ltd.281
  STATegics, Inc.291
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Drug Profiles3020
  avatrombopag Drug Profile302
  eltrombopag olamine Drug Profile326
  eltrombopag olamine Drug Profile381
  GSK-2285921 Drug Profile392
  lusutrombopag Drug Profile411
  Monoclonal Antibody to Agonize TpoR for Thrombocytopenia Drug Profile421
  romiplostim Drug Profile433
  romiplostim biosimilar Drug Profile461
  STST-4 Drug Profile471
  thrombopoietin Drug Profile481
  thrombopoietin Drug Profile491
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Dormant Projects501
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Discontinued Products511
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Featured News &Press Releases5215
  Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder521
  May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association531
  Apr 19, 2016: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia542
  Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP561
  Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag571
  Dec 01, 2015: Shionogi Launches MULPLETA Tablets 3mg In Japan for Improvement of Thrombocytopenia581
  Sep 28, 2015: Shionogi Receives Marketing and Manufacturing Approval in Japan for MULPLETA Tablets 3mg for Improvement of Thrombocytopenia581
  Sep 02, 2015: Novartis receives EU approval for new Revolade use as first-in-class therapy for patients with severe aplastic anemia591
  Aug 24, 2015: FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia601
  Jul 24, 2015: Novartis drug Revolade recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder611
  Jun 12, 2015: FDA Approves Promacta for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication621
  Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder632
  May 27, 2015: Amgen To present data from Nplate study at the 20th Congress of the EHA651
  Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade)651
  Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta)661
Appendix672
  Methodology671
  Coverage671
  Secondary Research671
  Primary Research671
  Expert Panel Validation671
  Contact Us671
  Disclaimer681

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Thrombopoietin-Receptor-Myeloproliferative-Leukemia-Protein-or-Proto-Oncogene-c-Mpl-or-CD110-or-MPL-Pipeline-Review-H1-2016-2088-16084>
  
APA:
Global Markets Direct - Market Research. (2016). Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Thrombopoietin-Receptor-Myeloproliferative-Leukemia-Protein-or-Proto-Oncogene-c-Mpl-or-CD110-or-MPL-Pipeline-Review-H1-2016-2088-16084>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.